Publications by authors named "M Drolet"
Article Synopsis
- - The study investigates the cost-effectiveness of expanding HPV vaccination to U.S. adults aged 27-45, particularly those at higher risk for HPV-related diseases, by modeling the potential outcomes over a 100-year timeframe.
- - It found that vaccinating mid-adults generally costs more per life year gained compared to vaccinating younger individuals, with varying costs and effectiveness depending on risk factors like number of sexual partners and recent relationship status.
- - The most efficient strategy identified was vaccinating women who have recently separated and have many lifetime partners, offering a lower cost per quality-adjusted life-year and fewer individuals needed to vaccinate to prevent one cancer case.
Background: A concern in high-income countries is that switching to 1-dose human papillomavirus (HPV) vaccination could cause a rebound in HPV infection and cervical cancer if 1-dose efficacy or duration were inferior to 2 doses. Using mathematical modeling and up-to-date trial-based data, we projected the population-level effectiveness of switching from 2-dose to 1-dose vaccination under different vaccine efficacy and duration assumptions in high-income countries.
Methods: We used HPV-ADVISE (Agent-based Dynamic model for VaccInation and Screening Evaluation), a transmission-dynamic model of HPV infection and cervical cancer, varying key model assumptions to identify those with the greatest impact on projections of HPV-16 and cervical cancer incidence over time: 1) 1-dose vaccine efficacy and vaccine duration, 2) mechanisms of vaccine efficacy and duration over time, 3) midadult (>30 years of age) sexual behavior, 4) progression to cervical cancer among midadults, and 5) vaccination coverage and programs.
Article Synopsis
- The study simulated how different HPV vaccination strategies affect cervical cancer cases over 85 years, focusing on switching from a 2-dose to a 1-dose program.
- It utilized two mathematical models to predict the outcomes based on different scenarios, such as introducing a 1-dose vaccination and varying age groups for vaccination.
- Results showed that switching to a 2-dose program in 2036 could yield similar health benefits to starting with a 1-dose vaccine with no effectiveness loss, indicating potential efficiency for countries considering the 1-dose option.
Background: Worldwide, countries are examining whether to implement 1-dose human papillomavirus (HPV) vaccination instead of using 2 doses. To inform policy, we sought to project the population-level impact and efficiency of switching from 2-dose to 1-dose gender-neutral routine HPV vaccination in Canada.
Methods: We used HPV-ADVISE, an individual-based transmission-dynamic model of HPV infections and diseases, to mathematically model vaccination programs in 2 provinces, Quebec, a province with high HPV vaccination coverage (around 85%), and Ontario, which has lower coverage (around 65%).
Article Synopsis
- * An exploratory study conducted interviews with 13 MHPs in Quebec to gather qualitative data on their experiences and perceptions of RC courses, revealing ten key themes regarding course format, expectations, and shared knowledge.
- * Participants noted significant changes in their professional practices, increased awareness of personal and clinical challenges, and improved overall well-being, indicating the value of group dynamics and course design in the training process.